

April 6, 2020

**Announcement on Candidates of Members of the Board of Directors,
Members of Audit & Supervisory Board and Corporate Officers, and
Resignation of Audit & Supervisory Board Member**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara) announced that the Company decided the following appointments for candidates of Members of the Board of Directors, Members of Audit & Supervisory Board and Corporate Officers at its Board of Directors meeting held today. The company also announced that one of the Members of Audit & Supervisory Board resigned on March 27.

The appointments for candidates of Members of the Board of Directors and Members of Audit & Supervisory Board will be resolved at the 72nd Annual Shareholders Meeting to be held in the mid of June 2020. The changes and appointments of Members of the Board of Directors and Corporate Officers will be officially decided at the Board of Directors meeting to be held on the same day of the Annual Shareholders Meeting.

1. Changes of Members of the Board of Directors (as of mid of June 2020):
Incumbent Members of the Board of Directors will be re-appointed.

1.1 New candidate of Members of the Board of Directors

- Toshihiro Tsujinaka Corporate Executive Officer / Executive Director, Corporate Strategy & Planning / Senior Director, Business Design
- Toichi Takino Corporate Executive Officer / Executive Director, Discovery & Research
- Outside Members of the Board of Directors

Name	Akiko Okuno	
Date of Birth	November 17, 1970	
Career Summary	Apr. 2002	Associate Professor, Faculty of Economics, Osaka University of Economics and Law
	Apr. 2004	Associate Professor, Faculty of Business Administration, Tezukayama University
	Apr. 2010	Professor, Faculty of Business Administration, Tezukayama University
	Apr. 2012	Professor, Faculty of Business Administration, KONAN UNIVERSITY (to date)
Reasons for nomination	Although Akiko Okuno has never been directly involved in corporate management, she has extensive academic knowledge as a university professor specializing in business administration. Since the Company can expect valuable advice and suggestions based on her knowledge in specialized fields, such as women's labor and personnel evaluation systems, we believe that she will contribute to the enhancement of corporate value and have nominated her as an outside director candidate.	

1.2 Resigning Members of the Board of Directors

- Kei Sano Member of the Board of Directors, Senior Executive Officer / Special Appointive Officer to President / Chief Officer CMC-Production
* After resigning, he will be appointed as a senior partner.
- Kazuhito Kawabata Member of the Board of Directors, Executive Officer / Chairman, Scientific Review Committee of R&D Programs
* After resigning, he will be appointed as a senior partner.
- Yutaka Kato Member of the Board of Directors, Outside Director

2. Members of Audit & Supervisory Board (as of mid of June 2020):

2.1 Reappointed candidates of Members of Audit & Supervisory Board

Katsuyoshi Nishimura (full-time) and Yasuo Hishiyama (outside) will be re-appointed.

2.2 New candidate of outside Members of Audit & Supervisory Board

Name	Akiko Tanabe	
Date of Birth	June 15, 1970	
Career Summary	Oct. 1993	Joined Century Audit Corporation (Present: Ernst & Young ShinNihon LLC)
	May 1997	Registered as Certified Public Accountant
	Jan. 2012	Established Akiko Tanabe CPA office (to date)
	Jun. 2015	Outside Director, OIE SANGYO CO., LTD. (to date)
	Jul. 2019	Partner of Midosuji Audit Corporation (to date)
Reasons for nomination	Although Akiko Tanabe has never been directly involved in corporate management, she has knowledge and experience as a certified public accountant. In this term, the Company has judged that she will be able to properly pursue her duties as an outside Audit & Supervisory Board Member and nominated her as an outside board member candidate	

3. Resignation of Corporate Auditors

Hiromi Sakka has resigned as an outside Audit & Supervisory Board Member on March 27, 2020, in order to undergo medical treatment. Accordingly, since the number of outside Audit & Supervisory Board Members has fallen below the number stipulated in laws and regulations, the Company has filed a petition to elect a provisional Audit & Supervisory Board Member (temporary acting Audit & Supervisory Board Member) to the Osaka District Court (currently under trial).

4. Changes of Corporate Officers (as of mid of June 2020)

Except for the following candidates of Corporate Officers, incumbent Corporate Officers will be re-appointed.

4.1 New candidates of Corporate Officer (as of mid of June 2020):

Senior Executive Officer:

- Hiroshi Ichikawa Executive Director, Sales and Marketing

Executive Officers:

- Shozo Matsuoka Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance
- Kiyooki Idemitsu Executive Director, Clinical Development

<Reference>

The followings are the appointments of Members of the Board of Directors, Members of Audit & Supervisory Board as well as Corporate Officers (as of mid of June 2020).

*: Candidates of Members of the Board of Directors and Members of Audit & Supervisory Board for subject to approval at the 72nd Annual Shareholders Meeting

Members of the Board of Directors:

- Gyo Sagara* President, Representative Director, and Chief Executive Officer
- Hiroshi Awata* Vice President Executive Officer, Tokyo Branch Head
- Isao Ono* Executive Officer, Director, Corporate Research
- Toshihiro Tsujinaka* Executive Director, Corporate Strategy & Planning / Senior Director, Business Design
- Toichi Takino* Executive Director, Discovery & Research
- Jun Kurihara* Outside Director
- Masao Nomura* Outside Director
- Akiko Okuno* Outside Director

Members of Audit & Supervisory Board

- Katsuyoshi Nishimura* Audit & Supervisory Board Member
- Shinji Fujiyoshi Audit & Supervisory Board Member
- Yasuo Hishiyama* Outside Audit & Supervisory Board Member
- Akiko Tanabe* Outside Audit & Supervisory Board Member

Corporate Officers:

- Hiroshi Ichikawa Corporate Senior Executive Officer, Executive Director, Sales and Marketing
- Yukio Tani Corporate Executive Officer, Head of Corporate Communications
- Shozo Matsuoka Corporate Executive Officer, Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance
- Kiyooki Idemitsu Corporate Executive Officer, Executive Director, Clinical Development
- Katsuji Teranishi Corporate Officer, Division Director, Sales Division, Western Japan Region
- Takuya Seko Corporate Officer, Executive Director, CMC-Production
- Hiromu Habashita Corporate Officer, Deputy Executive Director, Discovery & Research
- Katsunori Morio Corporate Officer, Division Director, Sales Division, Metropolitan Region
- Shinji Takai Corporate Officer, Head of Medical Affairs / Head of Data Strategy
- Keiji Masui Corporate Officer, Division Director, Sales Division, Eastern Japan Region

Ono Pharmaceutical Co., Ltd.

Corporate Communications

public_relations@ono.co.jp